James Ong, MD
Clinical Cardiac Electrophysiology · Tarzana, CANPI 1912955980
Payments from drug & device makers
Across 812 payments — averaging $35.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$7K
- Biosense Webster, Inc.$4K
- Johnson & Johnson$1K
- Boehringer Ingelheim$1K
- Boston Scientific$1K
- plus $6K from 30 others
What the payments were for
- Consulting fees$1,2504%
- Travel & lodging$4,27615%
- Food & beverage$23,53481%
- Education$1140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 151 | $8,788 |
| Abbott | 144 | $6,761 |
| Biosense Webster, Inc. | 104 | $3,647 |
| Johnson & Johnson | 64 | $1,364 |
| Boehringer Ingelheim | 53 | $1,124 |
| Boston Scientific | 27 | $1,063 |
| E.r. Squibb & Sons, L.L.C. | 54 | $934 |
| Pfizer | 37 | $742 |
| Novartis | 32 | $608 |
| Merck | 30 | $538 |
| Atricure, Inc. | 8 | $522 |
| AstraZeneca | 17 | $483 |
| Sanofi-aventis U.S. LLC | 14 | $355 |
| Alnylam Pharmaceuticals Inc. | 11 | $253 |
| Acutus Medical, Inc. | 3 | $231 |
| Amgen | 7 | $181 |
| Impulse Dynamics (USA) Inc. | 5 | $174 |
| Bridgebio Pharma, Inc. | 4 | $154 |
| Cordis US CORP. | 7 | $152 |
| Biotronik Inc. | 5 | $136 |
| Bayer | 5 | $118 |
| Kestra Medical Technology Services, Inc. | 3 | $109 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $108 |
| Cardiva Medical, Inc. | 4 | $102 |
| Bardy Diagnostics, Inc. | 3 | $78 |
| Novo Nordisk | 3 | $68 |
| Cvrx, Inc. | 1 | $59 |
| Lexicon Pharmaceuticals, Inc. | 2 | $52 |
| Edwards Lifesciences | 1 | $51 |
| Convatec Inc. | 2 | $50 |
| Heartflow, Inc. | 2 | $42 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $33 |
| Baxter Healthcare | 1 | $28 |
| Elutia, Inc. | 1 | $27 |
| KCI USA, Inc. | 1 | $23 |
| Medicomp Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$1,250
- Arctic Front$894
- QDOT MICRO Catheter$439
- Watchman$396
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$293
- Quadra Assura CRT Defibrillator$260
- PulseSelect$162
- AVEIR$142
- AFFERA MAPPING SYSTEM$136
- AZURE XT DR MRI SURESCAN$135
- XARELTO$125
- FARXIGA$125
- ASSURITY$124
- LINQ II$121
How this compares
$29,174 in reported general payments places this provider in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 367 | $404,629 |
| XareltoRivaroxaban | 141 | $191,611 |
| EntrestoSacubitril/Valsartan | 156 | $171,310 |
| JardianceEmpagliflozin | 119 | $130,512 |
| MultaqDronedarone Hcl | 54 | $69,453 |
| FarxigaDapagliflozin Propanediol | 30 | $27,476 |
| DapagliflozinDapagliflozin Propanediol | 16 | $7,690 |
| InpefaSotagliflozin | 11 | $6,625 |
| Amiodarone Hcl | 112 | $5,284 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 79 | $2,171 |
| Flecainide Acetate | 68 | $1,951 |
| Propafenone Hcl | 28 | $1,437 |
| Valsartan | 51 | $1,258 |
| Metoprolol Succinate | 75 | $1,189 |
| Amlodipine Besylate | 77 | $1,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $742 | $404,629367 claims |
| Johnson & JohnsonXarelto | $1,364 | $191,611141 claims |
| NovartisEntresto | $608 | $171,310156 claims |
| Boehringer IngelheimJardiance | $1,124 | $130,512119 claims |
| Sanofi-aventis U.S. LLCMultaq | $355 | $69,45354 claims |
| AstraZenecaFarxiga | $483 | $27,47630 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $52 | $6,62511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Tarzana
- David KrummenSan Diego$7.3M
- Jonathan DukesVentura$2.9M
- Shephal DoshiSanta Monica$2.9M
- Arash AryanaSacramento$2.4M
- Marco PerezStanford$2.1M
- Rahul DoshiLos Angeles$2M
- Mayer RashtianPasadena$1.8M
- Rajesh BankerNewport Beach$1.6M
- Edward GerstenfeldSan Francisco$1.5M
- Jonathan HsuSan Diego$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.